奥利万星与其他药物对万古霉素敏感和耐药肠球菌的体外活性比较 - Suppr

Suppr

超能文献

Comparative in vitro activity of oritavancin and other agents against vancomycin-susceptible and -resistant enterococci.

作者信息

Sweeney Debora, Stoneburner Audrey, Shinabarger Dean L, Arhin Francis F, Belley Adam, Moeck Greg, Pillar Chris M

机构信息

Micromyx, LLC, Kalamazoo, MI, USA.

The Medicines Company, Ville Saint Laurent, Québec, Canada.

出版信息

J Antimicrob Chemother. 2017 Feb;72(2):622-624. doi: 10.1093/jac/dkw451. Epub 2016 Nov 17.

DOI:10.1093/jac/dkw451

PMID:27856721

Abstract

摘要

相似文献

Comparative in vitro activity of oritavancin and other agents against vancomycin-susceptible and -resistant enterococci.

J Antimicrob Chemother. 2017 Feb;72(2):622-624. doi: 10.1093/jac/dkw451. Epub 2016 Nov 17.

Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium.

J Antimicrob Chemother. 2009 Jun;63(6):1191-9. doi: 10.1093/jac/dkp126. Epub 2009 Apr 15.

In vitro activity of oritavancin and comparator agents against staphylococci, streptococci and enterococci from clinical infections in Europe and North America, 2011-2014.

Int J Antimicrob Agents. 2015 Dec;46(6):674-81. doi: 10.1016/j.ijantimicag.2015.08.014. Epub 2015 Oct 20.

In vitro stepwise selection of reduced susceptibility to lipoglycopeptides in enterococci.

Diagn Microbiol Infect Dis. 2017 Oct;89(2):168-171. doi: 10.1016/j.diagmicrobio.2017.06.023. Epub 2017 Jul 1.

In vitro activity of oritavancin against Gram-positive pathogens isolated in Canadian hospital laboratories from 2011 to 2013.

Diagn Microbiol Infect Dis. 2014 Dec;80(4):311-5. doi: 10.1016/j.diagmicrobio.2014.09.003. Epub 2014 Sep 16.

Evaluation of Oritavancin Dosing Strategies against Vancomycin-Resistant Enterococcus faecium Isolates with or without Reduced Susceptibility to Daptomycin in an Pharmacokinetic/Pharmacodynamic Model.

Antimicrob Agents Chemother. 2017 Dec 21;62(1). doi: 10.1128/AAC.01873-17. Print 2018 Jan.

Comparative Pharmacodynamics of Single-Dose Oritavancin and Daily High-Dose Daptomycin Regimens against Vancomycin-Resistant Enterococcus faecium Isolates in an Pharmacokinetic/Pharmacodynamic Model of Infection.

Antimicrob Agents Chemother. 2017 Sep 22;61(10). doi: 10.1128/AAC.01265-17. Print 2017 Oct.

Oritavancin activity against vancomycin-susceptible and vancomycin-resistant Enterococci with molecularly characterized glycopeptide resistance genes recovered from bacteremic patients, 2009-2010.

Antimicrob Agents Chemother. 2012 Mar;56(3):1639-42. doi: 10.1128/AAC.06067-11. Epub 2011 Dec 19.

Longitudinal (2001-14) analysis of enterococci and VRE causing invasive infections in European and US hospitals, including a contemporary (2010-13) analysis of oritavancin in vitro potency.

J Antimicrob Chemother. 2016 Dec;71(12):3453-3458. doi: 10.1093/jac/dkw319. Epub 2016 Sep 8.

Activity of oritavancin against methicillin-resistant staphylococci, vancomycin-resistant enterococci and β-haemolytic streptococci collected from western European countries in 2011.

J Antimicrob Chemother. 2013 Jan;68(1):164-7. doi: 10.1093/jac/dks344. Epub 2012 Aug 30.

引用本文的文献

Vancomycin-Resistant : Addressing Global and Clinical Challenges.

Antibiotics (Basel). 2025 May 19;14(5):522. doi: 10.3390/antibiotics14050522.

Is an oritavancin catheter lock solution active against biofilms of staphylococci and enterococci?

Heliyon. 2025 Jan 10;11(2):e41885. doi: 10.1016/j.heliyon.2025.e41885. eCollection 2025 Jan 30.

Synthetic and Semisynthetic Compounds as Antibacterials Targeting Virulence Traits in Resistant Strains: A Narrative Updated Review.

Antibiotics (Basel). 2023 May 25;12(6):963. doi: 10.3390/antibiotics12060963.

Antimicrobial Susceptibility Testing for Enterococci.

J Clin Microbiol. 2022 Sep 21;60(9):e0084321. doi: 10.1128/jcm.00843-21. Epub 2022 Jun 13.

New Perspectives on Antimicrobial Agents: Long-Acting Lipoglycopeptides.

Antimicrob Agents Chemother. 2022 Jun 21;66(6):e0261420. doi: 10.1128/aac.02614-20. Epub 2022 Apr 27.

Molecular Dynamics Simulation of Atomic Interactions in the Vancomycin Binding Site.

ACS Omega. 2020 Dec 22;6(1):775-785. doi: 10.1021/acsomega.0c05353. eCollection 2021 Jan 12.

Continued Dosing of Oritavancin for Complicated Gram-Positive Infections.

Fed Pract. 2020 Nov;37(11):502-504. doi: 10.12788/fp.0068.

N-Terminal guanidine derivatives of teicoplanin antibiotics strongly active against glycopeptide resistant Enterococcus faecium.

J Antibiot (Tokyo). 2020 Sep;73(9):603-614. doi: 10.1038/s41429-020-0313-6. Epub 2020 May 15.

Antimicrob Agents Chemother. 2017 Sep 22;61(10). doi: 10.1128/AAC.01265-17. Print 2017 Oct.

Hidden Mode of Action of Glycopeptide Antibiotics: Inhibition of Wall Teichoic Acid Biosynthesis.

J Phys Chem B. 2017 Apr 27;121(16):3925-3932. doi: 10.1021/acs.jpcb.7b00324. Epub 2017 Apr 14.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验